## Radu Tanasescu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8273777/publications.pdf

Version: 2024-02-01

279487 168136 3,112 77 23 h-index citations papers

g-index 88 88 88 4523 docs citations times ranked citing authors all docs

53

#	Article	IF	CITATIONS
1	Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. European Journal of Neurology, 2011, 18, 19.	1.7	489
2	EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. European Journal of Neurology, 2010, 17, 1408-1418.	1.7	484
3	Prospective study of symptomatic atherothrombotic intracranial stenoses: The GESICA Study. Neurology, 2006, 66, 1187-1191.	1.5	289
4	Cannabinoids and the immune system: An overview. Immunobiology, 2010, 215, 588-597.	0.8	209
5	Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurologica Scandinavica, 2017, 135, 4-16.	1.0	134
6	Guillain–Barré Syndrome Variant Occurring after <scp>SARSâ€CoVâ€2</scp> Vaccination. Annals of Neurology, 2021, 90, 315-318.	2.8	134
7	Effects of proâ€inflammatory cytokines on cannabinoid <scp>CB</scp> <sub>1</sub> and <scp>CB</scp> <sub>2</sub> receptors in immune cells. Acta Physiologica, 2015, 214, 63-74.	1.8	95
8	Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 324-331.	0.9	95
9	Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e117.	3.1	86
10	The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0172415.	1.1	77
11	Functional reorganisation in chronic pain and neural correlates of pain sensitisation: A coordinate based meta-analysis of 266 cutaneous pain fMRI studies. Neuroscience and Biobehavioral Reviews, 2016, 68, 120-133.	2.9	70
12	Vasopressin neurotransmission and the control of circadian rhythms in the suprachiasmatic nucleus. Progress in Brain Research, 1999, 119, 351-364.	0.9	67
13	Status of diagnostic approaches to AQP4-lgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	1.8	60
14	Paraplegia due to non-osseous spinal tuberculosis: report of three cases and review of the literature. International Journal of Infectious Diseases, 2008, 12, 425-429.	1.5	41
15	Hookworm Treatment for Relapsing Multiple Sclerosis. JAMA Neurology, 2020, 77, 1089.	4.5	39
16	Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2. Journal of Neuroimmunology, 2017, 304, 11-20.	1.1	37
17	The Soluble Form of Toll-Like Receptor 2 Is Elevated in Serum of Multiple Sclerosis Patients: A Novel Potential Disease Biomarker. Frontiers in Immunology, 2018, 9, 457.	2.2	36
18	Siponimod for the treatment of secondary progressive multiple sclerosis. Expert Opinion on Pharmacotherapy, 2019, 20, 143-150.	0.9	33

#	Article	IF	CITATIONS
19	Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study. Nicotine and Tobacco Research, 2018, 20, 589-595.	1.4	32
20	Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. Journal of Neurology, 2004, 251, 762-3.	1.8	28
21	Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFN $\hat{I}^3$ /IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis. Journal of Neurolmmune Pharmacology, 2015, 10, 457-467.	2.1	28
22	Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large University Hospital. American Journal of Clinical and Experimental Immunology, 2014, 3, 57-67.	0.2	27
23	Comorbidity in multiple sclerosis: its temporal relationships with disease onset and dose effect on mortality. European Journal of Neurology, 2020, 27, 105-112.	1.7	26
24	Advances in the treatment of relapsing - Remitting multiple sclerosis. Biomedical Journal, 2014, 37, 41.	1.4	25
25	Do Antiretroviral Drugs Protect From Multiple Sclerosis by Inhibiting Expression of MS-Associated Retrovirus?. Frontiers in Immunology, 2018, 9, 3092.	2.2	24
26	Coordinate based random effect size meta-analysis of neuroimaging studies. NeuroImage, 2017, 153, 293-306.	2.1	23
27	MOG-lgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. Journal of Neurology, 2020, 267, 359-368.	1.8	22
28	Recent developments in interferon-based therapies for multiple sclerosis. Expert Opinion on Biological Therapy, 2018, 18, 665-680.	1.4	21
29	Coordinate Based Meta-Analysis of Functional Neuroimaging Data Using Activation Likelihood Estimation; Full Width Half Max and Group Comparisons. PLoS ONE, 2014, 9, e106735.	1.1	20
30	Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis. Neurology and Therapy, 2019, 8, 45-57.	1.4	20
31	Coordinate Based Meta-Analysis of Functional Neuroimaging Data; False Discovery Control and Diagnostics. PLoS ONE, 2013, 8, e70143.	1.1	18
32	Neurotoxicity of immunosuppressive therapies in organ transplantation. M $ ilde{A}^{\dagger}_{l}$ dica, 2013, 8, 170-5.	0.4	18
33	Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. Journal of NeuroVirology, 2017, 23, 839-844.	1.0	17
34	Experimental infection with the hookworm, Necator americanus, is associated with stable gut microbial diversity in human volunteers with relapsing multiple sclerosis. BMC Biology, 2021, 19, 74.	1.7	17
35	The Potential for EBV Vaccines to Prevent Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	17
36	Epilepsy and associated mortality in patients with multiple sclerosis. European Journal of Neurology, 2019, 26, 342.	1.7	16

#	Article	IF	Citations
37	A different response to cytomegalovirus (CMV) and Epstein–Barr virus (EBV) infection in UK people with multiple sclerosis (PwMS) compared to controls. Journal of Infection, 2020, 80, 320-325.	1.7	16
38	Helminth Therapy for MS. Current Topics in Behavioral Neurosciences, 2014, 26, 195-220.	0.8	15
39	Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?. Multiple Sclerosis Journal, 2017, 23, 1050-1055.	1.4	15
40	The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease. Amino Acids, 2013, 45, 95-112.	1.2	13
41	Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 621-630.	1.5	13
42	Coordinate based meta-analysis does not show grey matter atrophy in narcolepsy. Neuroscience and Biobehavioral Reviews, 2015, 57, 297-298.	2.9	13
43	Reduced Myelin Signal in Normal-appearing White Matter in Neuromyelitis Optica Measured by 7T Magnetic Resonance Imaging. Scientific Reports, 2019, 9, 14378.	1.6	13
44	Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment, 2013, 9, 539.	1.0	12
45	Diagnostic modalities in multiple sclerosis: Perspectives in children. Biomedical Journal, 2014, 37, 50.	1.4	11
46	PEGylated IFN $\hat{I}^2$ -1a in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy, 2015, 15, 1077-1084.	1.4	10
47	Sevenâ€Tesla Magnetization Transfer Imaging to Detect Multiple Sclerosis White Matter Lesions. Journal of Neuroimaging, 2018, 28, 183-190.	1.0	10
48	Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1219-1228.	1.5	9
49	Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 691-697.	0.2	9
50	TLR2 - an innate immune checkpoint in multiple sclerosis. Oncotarget, 2015, 6, 35131-35132.	0.8	8
51	The future of multiple sclerosis treatments. Expert Review of Neurotherapeutics, 2016, 16, 1341-1356.	1.4	7
52	Localised Grey Matter Atrophy in Multiple Sclerosis and Clinically Isolated Syndrome—A Coordinate-Based Meta-Analysis, Meta-Analysis of Networks, and Meta-Regression of Voxel-Based Morphometry Studies. Brain Sciences, 2020, 10, 798.	1.1	7
53	A drug discovery case history of â€~delta-9-tetrahydrocannabinol, cannabidiol'. Expert Opinion on Drug Discovery, 2011, 6, 437-452.	2.5	6
54	Coordinate based meta-analysis does not show grey matter atrophy in narcolepsy. Neuroscience and Biobehavioral Reviews, 2019, 102, 427-429.	2.9	6

#	Article	IF	Citations
55	Coordinate based meta-analysis of networks in neuroimaging studies. Neurolmage, 2020, 205, 116259.	2.1	6
56	Increased IL-2 and Reduced TGF-Î <sup>2</sup> Upon T-Cell Stimulation are Associated with GM-CSF Upregulation in Multiple Immune Cell Types in Multiple Sclerosis. Biomedicines, 2020, 8, 226.	1.4	6
57	Neurological Disorders Associated With COVID-19 Hospital Admissions: Experience of a Single Tertiary Healthcare Center. Frontiers in Neurology, 2021, 12, 640017.	1.1	6
58	Age at onset predicts outcome in aquaporin-4-lgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. Journal of the Neurological Sciences, 2021, 431, 120039.	0.3	5
59	Easy to interpret coordinate based meta-analysis of neuroimaging studies: Analysis of brain coordinates (ABC). Journal of Neuroscience Methods, 2022, 372, 109556.	1.3	4
60	Decreased interferon- $\hat{l}^2$ induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis. Acta Neurologica Scandinavica, 2017, 136, 233-238.	1.0	3
61	Antiphospholipid antibodies and migraine: a retrospective study of 428 patients with inflammatory connective tissue diseases. Romanian Journal of Internal Medicine, 2007, 45, 355-63.	0.4	3
62	An Absence of Epstein–Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination. Vaccines, 2020, 8, 487.	2.1	2
63	Wernicke's Encephalopathy. , 0, , .		1
64	Posttransplantation Encephalopaties., 0,,.		1
65	Central Nervous System Involvement in Lyme Disease - Making the Diagnosis and Choosing the Correct Treatment. , 0, , .		1
66	Guilty by association? SARS oVâ€⊋ antibodies and myelin oligodendrocyte glycoprotein antibodyâ€associated disease. European Journal of Neurology, 2022, , .	1.7	1
67	Effects of substance P on human cerebral microvascular endothelial cell line hCMEC/D3 are mediated exclusively through a truncated NK-1 receptor and depend on cell confluence. Neuropeptides, 2022, 95, 102265.	0.9	1
68	Granulocyte-macrophage colony-stimulating factor: Increased expression by immune cells of patients with multiple sclerosis. Journal of the Neurological Sciences, 2015, 357, e15.	0.3	0
69	Intestinal Parasites and Immunomodulation in Neuroinflammatory Disease., 2016,, 189-209.		0
70	Coordinate based meta analysis of voxel based morphometry studies does not show evidence of specific grey matter loss in posttraumatic stress disorder. European Neuropsychopharmacology, 2019, 29, S287-S288.	0.3	0
71	Uncovering the underhanded: B-cell depletion therapies and severe viral infections – Commentary on †Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease'. Multiple Sclerosis Journal, 2021, 27, 323-324.	1.4	0
72	The Effects of Cannabinoids on Immune Cells, Responses and Diseases. , 2012, , 307-359.		0

#	Article	IF	CITATIONS
73	A THREE-STEP EXAMINATION IN DIFFERENTIATING PERIPHERAL FROM CENTRAL VERTIGO. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2016, 15, 52-54.	0.1	0
74	Atypical X-linked adult adrenoleukodystrophy with cerebellar and brainstem involvement - a case report. Endocrine Abstracts, $0$ , , .	0.0	0
75	ANTI AQUAPORIN 4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER AND PRIMARY SJ×GREN SYNDROME FOLLOWING SUCCESSFUL THERAPY FOR CHRONIC HEPATITIS C – REPORT OF A CLINICAL CASE. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2017, 16, 74-77.	0.1	0
76	MULTIPLE CEREBRAL MELANOMA METASTASES WITH UNKNOWN PRIMARY TUMOR LOCATION: A CASE REPORT. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2017, 16, 175-178.	0.1	0
77	Primary versus Secondary Central Nervous System Melanoma: a Diagnostic Dilemma and Report of a Case. Medicina Moderna, 2019, 26, 35-39.	0.0	O